In a Wednesday report, analyst Ngoh Yi Sin notes that the group saw a comparatively stronger 2Q18 in terms of core PATMI, which would have been RM257 million or 198% higher y-o-y if not for exceptional items.
SINGAPORE (Aug 29): CGS-CIMB Research is maintaining its “add” recommendation on IHH Healthcare with a lower target price of RM6.63 ($2.21) compared to RM6.86 previously, even as the dual-listed Malaysian private healthcare operator’s 2H18 results missed expectations slightly.
This comes after IHH Healthcare reported 48% lower 2Q18 earnings of RM165.11 million from a year ago in the absence of a one-off divestment gain related to Apollo Hospitals which was recorded in 2Q17.
